Compare · ORKA vs TRIB
ORKA vs TRIB
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Trinity Biotech plc (TRIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and TRIB operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.76B, about 271.1x TRIB ($13.9M).
- Over the past year, ORKA is up 410.2% and TRIB is up 11.7% - ORKA leads by 398.5 points.
- ORKA has been more active in the news (15 items in the past 4 weeks vs 8 for TRIB).
- ORKA has more recent analyst coverage (11 ratings vs 0 for TRIB).
- Company
- Oruka Therapeutics Inc.
- Trinity Biotech plc
- Price
- $62.29+8.84%
- $0.71-0.17%
- Market cap
- $3.76B
- $13.9M
- 1M return
- -9.70%
- +18.18%
- 1Y return
- +410.16%
- +11.68%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 15
- 8
- Recent ratings
- 11
- 0
Trinity Biotech plc
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)
Latest TRIB
- SEC Form AW filed by Trinity Biotech plc
- SEC Form POS AM filed by Trinity Biotech plc
- SEC Form RW filed by Trinity Biotech plc
- Amendment: SEC Form F-1/A filed by Trinity Biotech plc
- SEC Form 424B3 filed by Trinity Biotech plc
- SEC Form EFFECT filed by Trinity Biotech plc
- SEC Form F-3 filed by Trinity Biotech plc
- SEC Form F-3 filed by Trinity Biotech plc
- SEC Form 6-K filed by Trinity Biotech plc
- Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations